The spread of drug-resistant bacteria is a global health concern and could once again become a leading cause of mortality. The World Health Organization has flagged carbapenem-resistant Acinetobacter ...

Venture Capital firm Asabys Partners closed its second fund, Sabadell Asabys Health Innovation Investments II, with total commitments of €180 million ($200 million). The funds will go towards 12 to 15 ...

The FDA has approved Cobenfy, a dual M1/M4 muscarinic agonist that offers a fundamentally different approach to treating ...

In one of the largest private rounds raised by an Italian biotech, Genespire Srl has closed a €46.6 million (US$51.88 million) series B, enabling it to lay the ground for a phase I/II clinical trial ...

Insilico Medicine Inc. has synthesized cyclin-dependent kinase 8/19 (CDK8/19) dual inhibitors reported to be useful for the treatment of autoimmune disease and cancer.

Spanish VC firm Asabys Partners has closed its second fund at €180 million (US$201.3 million), to be invested in seed to ...

China’s National Medical Products Administration (NMPA) has accepted NDAs for Innovent Biologics Inc.’s IL-23p19 antibody ...

In some ways, remote patient monitoring (RPM) came of age during the COVID-19 pandemic, but payers still worry about the ...

A new series of proteolytic targeting chimeras (PROTACs) was designed by Zhejiang University of Technology scientists based ...

Endometrial cancer (EC) accounts for 20% to 30% of most malignant tumors of the female reproductive system, making it one of ...

The U.S. FDA’s approval of yet another indication for Dupixent (dupilumab), partnered between Regeneron Pharmaceuticals Inc. and Sanofi SA, could mean another $6.4 billion-plus in sales by the end of ...

In August 2024, BioWorld tracked 92 clinical trial updates, a decrease from the 121 reported in July. The month included nine successful phase III trials, three with mixed outcomes and three failures.